Sialorrhoea Management
On this page
Direct answer
Drooling is more often a swallowing problem than an excess-saliva problem: in most patients with sialorrhoea, production is normal and oromotor control — swallowing frequency, lip closure, head posture — is impaired, as in cerebral palsy, Parkinsonism, stroke and motor neuron disease. Management therefore climbs a conservative-to-invasive ladder: orofacial physiotherapy and behaviour training first, intraoral training appliances next, then anticholinergic medication (glycopyrrolate, transdermal hyoscine), botulinum toxin A into the major salivary glands giving three to six months of relief, and finally surgery — duct rerouting, duct ligation or gland excision — for refractory severe cases. Posterior drooling, which spills over the tongue base, raises aspiration risk and accelerates the whole ladder.
What you must remember
- Redefine before treating: true hypersalivation (teething, gastro-oesophageal reflux, oesophageal obstruction, heavy-metal or organophosphate exposure) is rare; impaired swallow with normal flow (cerebral palsy in children, Parkinsonism in adults) is the rule.
- Anterior versus posterior drooling: anterior spill is the social problem; posterior spill risks aspiration pneumonitis — the distinction decides urgency.
- Step one is non-invasive: orofacial exercises, swallowing and behaviour therapy, biofeedback, head-position control, and palatal training appliances (bead-on-wire plates that cue lip closure) in cooperative children.
- Anticholinergic drugs: glycopyrrolate — quaternary, crosses the blood-brain barrier poorly, hence preferred in cerebral palsy; transdermal hyoscine (72-hour patch); amitriptyline at night. Shared adverse effects: dry mouth, constipation, urinary retention, blurred vision; caution in glaucoma.
- Botulinum toxin type A into the parotids (± submandibular glands), usually ultrasound-guided: benefit for roughly three to six months, repeatable — now a first-line invasive option in most centres.
- Surgery is last: submandibular duct rerouting, duct ligation or gland excision for refractory disease; older denervation procedures (tympanic neurectomy, chorda tympani section) are largely historical.
- Measure the outcome: the Drooling Severity and Frequency Scale or Teacher Drooling Scale quantifies baseline and response — the instruments trials quote.
One child, the whole ladder
An eight-year-old with severe cerebral palsy soaks a bib hourly, has perioral maceration and two hospitalisations for chest infection — the last detail signalling posterior drooling and aspiration risk, which sets the pace. Baseline severity is scored on the Drooling Scale. First tier: speech and orofacial therapy targeting lip closure, tongue control and scheduled swallowing, posture management in the wheelchair, and behaviour cues to swallow; three to six months of honest trial. Second tier, since attention allows it: a palatal training plate with a stimulating bead, worn by day. Third tier, pharmacological: oral glycopyrrolate, started low and titrated, watching for constipation and urinary retention; a hyoscine patch is the alternative where tablets are refused. If benefit is partial or adverse effects limit dosing, botulinum toxin A is injected into both parotids under ultrasound guidance, with effect reviewed at four to six weeks and repeated roughly twice a year. Only if the combination fails — or aspiration pneumonia recurs — does the case go for submandibular duct rerouting with or without gland excision, accepting a trade toward dryness that must not tip into xerostomia and its caries. At every stage the dentist also protects the teeth and treats the macerated perioral skin.
How the exam frames it
The single most repeated stem is "a child with cerebral palsy and persistent drooling — first line of management", and the intended sequence begins with conservative therapy and anticholinergies, not surgery; candidates who jump to gland excision answer the final option as if it were the first. The pharmacology frame tests the blood-brain barrier logic: glycopyrrolate's quaternary structure keeps it out of the central nervous system, which is exactly why it is preferred over atropine-like agents in a neurologically disabled child. The definition frame asks why drooling occurs with normal salivation — the answer being reduced automatic swallowing and impaired oral containment — and a final favourite asks which pattern threatens the airway: posterior, not anterior, drooling. Attach aspiration to posterior, glycopyrrolate to cerebral palsy, and botulinum toxin to the middle of the ladder, and this topic is banked.
Frequently asked questions
What is the commonest pathological cause of sialorrhoea in children?
Cerebral palsy — normal saliva production with impaired oromotor control and reduced swallow frequency, not gland hypersecretion.
Why is glycopyrrolate preferred among anticholinergics?
Its quaternary ammonium structure limits blood-brain barrier penetration, reducing central adverse effects while still drying the glands peripherally.
What is the role of botulinum toxin in sialorrhoea?
Ultrasound-guided injection into the parotid (± submandibular) glands reduces flow for about three to six months, repeatable, as a first-line invasive option before surgery.
Which pattern of drooling risks aspiration?
Posterior drooling — saliva spilling over the tongue base into the pharynx — associated with recurrent chest infection and faster escalation of treatment.
Name the surgical options for refractory sialorrhoea.
Submandibular duct rerouting, salivary duct ligation and salivary gland excision — reserved for severe cases failing conservative and pharmacological therapy.